Onxeo Announces Evolution In The Board Of Directors
Mr. Patrick Langlois is planning to step down from the chairmanship in early 2016 for personal reasons
Mr. Joseph Zakrzewski is joining the Board and is expected to be appointed Non-Executive Chairman in 2016
Paris (France), Copenhagen (Denmark), October 6, 2015 - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, today announced that Mr. Joseph Zakrzewski is joining the Board of Directors as a Permanent Attendee with the view of being appointed Board Member and Non-Executive Chairman early 2016. Mr. Patrick Langlois, currently Non-Executive Chairman of the Board, has announced that he will step down from his chairmanship and board position for personal reasons and will pass his responsibility to Mr. Zakrzewski after the board meeting scheduled for the end of January 2016.
When Mr. Joseph Zakrzewski is appointed as chairman, Mrs. Danièle Guyot-Caparros, board member and Chairman of the Audit Committee, will be appointed Senior Independent Director in charge of good governance practices, especially in the French environment.
Mr. Joseph Zakrzewski has more than 25 years of experience in the global healthcare industry with a focus in the United States, where he has successfully handled leadership positions in public and private companies as well as venture capital. Throughout his career, he has developed an extensive range of expertise, heading Global Corporate Business Development for Eli Lilly prior to being appointed to executive positions at biotechnology companies (Reliant Pharmaceuticals, Xcellerex, and Amarin) where he acquired a broad knowledge of the US biotechnology environment, innovation management, and healthcare-specialized financing. Mr. Zakrzewski currently holds board member positions with a number of US and European healthcare companies.
"We are delighted to welcome Joe to Onxeo. His experience in corporate development, his knowledge of the US healthcare environment and the financial community are impressive and I am pleased to hand over my responsibilities to him. We are convinced that Joe will bring a sound value to the Board of Directors in supporting the management team as it continues to drive the company forward. Over the coming months we are planning on a smooth transition in early 2016" comments Patrick Langlois, Chairman of the Board of Onxeo. "I have been privileged to witness and contribute to Onxeo's new focus on high potential orphan oncology products. I am very proud of what we have achieved, together with the Board of Directors and the management team that I would like to thank them both for their trust and commitment".
Mr. Joseph Zakrzewski, Permanent Attendee and future Chairman of the Board of Directors of Onxeo, added: "Onxeo is a very promising company with a clear position in an attractive market, a large and well-advanced pipeline and a strong management team. I am delighted to join Onxeo's board, a group of highly experienced professionals and I am impressed with the level of commitment and professionalism shown within the company. I truly believe that this company has everything it needs to build a great future and I am very excited to have the opportunity to be part of this entrepreneurial adventure that I will support in all possible ways".
Biography:
Joseph Zakrzewski has more than 25 years of experience in the healthcare industry. His career started with Eli Lilly & Company in the USA: He joined as process engineer with responsibility for biologics development & manufacturing (1988-1991), became Senior Financial Analyst (1991-1993) and Head of Manufacturing and Development (1993-1995), then Manager and Director of Corporate Business Development (1995-2003), before being appointed VP Global Corporate Business Development (2003-2005). He was Chief Operating Officer of Reliant Pharmaceuticals (2005-2007), and then joined the biotechnology company Xcellerex as CEO (2007-2010). From 2010 to 2013, he was Chairman and CEO of Amarin Corporation (Ireland), where he remains a director. He has also been a venture partner at Orbimed Advisors, one of the leading VC funds dedicated to the healthcare industry (2010-2011).
Joseph Zakrzewski is a board member with several biotechnology companies in Europe and in the USA, public and private, including Insulet Corporation, Amarin Corporation, Thrasos Therapeutics, Acceleron Pharma, Gliacure Inc., and SiteOne Therapeutics.
A US citizen, Joseph Zakrzewski received a BS in Chemical Engineering and an MS in Biochemical Engineering from Drexel University. He has an MBA in Finance from the University of Indiana.
About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to "make the difference". The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.
Key orphan oncology products at the advanced development stage are:
Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (clonidine Lauriad®): Phase II in severe oral mucositis: Positive final results
Beleodaq® (belinostat): Registered in the US in 2nd-line treatment of peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com
Help employers find you! Check out all the jobs and post your resume.
Mr. Joseph Zakrzewski is joining the Board and is expected to be appointed Non-Executive Chairman in 2016
Paris (France), Copenhagen (Denmark), October 6, 2015 - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, today announced that Mr. Joseph Zakrzewski is joining the Board of Directors as a Permanent Attendee with the view of being appointed Board Member and Non-Executive Chairman early 2016. Mr. Patrick Langlois, currently Non-Executive Chairman of the Board, has announced that he will step down from his chairmanship and board position for personal reasons and will pass his responsibility to Mr. Zakrzewski after the board meeting scheduled for the end of January 2016.
When Mr. Joseph Zakrzewski is appointed as chairman, Mrs. Danièle Guyot-Caparros, board member and Chairman of the Audit Committee, will be appointed Senior Independent Director in charge of good governance practices, especially in the French environment.
Mr. Joseph Zakrzewski has more than 25 years of experience in the global healthcare industry with a focus in the United States, where he has successfully handled leadership positions in public and private companies as well as venture capital. Throughout his career, he has developed an extensive range of expertise, heading Global Corporate Business Development for Eli Lilly prior to being appointed to executive positions at biotechnology companies (Reliant Pharmaceuticals, Xcellerex, and Amarin) where he acquired a broad knowledge of the US biotechnology environment, innovation management, and healthcare-specialized financing. Mr. Zakrzewski currently holds board member positions with a number of US and European healthcare companies.
"We are delighted to welcome Joe to Onxeo. His experience in corporate development, his knowledge of the US healthcare environment and the financial community are impressive and I am pleased to hand over my responsibilities to him. We are convinced that Joe will bring a sound value to the Board of Directors in supporting the management team as it continues to drive the company forward. Over the coming months we are planning on a smooth transition in early 2016" comments Patrick Langlois, Chairman of the Board of Onxeo. "I have been privileged to witness and contribute to Onxeo's new focus on high potential orphan oncology products. I am very proud of what we have achieved, together with the Board of Directors and the management team that I would like to thank them both for their trust and commitment".
Mr. Joseph Zakrzewski, Permanent Attendee and future Chairman of the Board of Directors of Onxeo, added: "Onxeo is a very promising company with a clear position in an attractive market, a large and well-advanced pipeline and a strong management team. I am delighted to join Onxeo's board, a group of highly experienced professionals and I am impressed with the level of commitment and professionalism shown within the company. I truly believe that this company has everything it needs to build a great future and I am very excited to have the opportunity to be part of this entrepreneurial adventure that I will support in all possible ways".
Biography:
Joseph Zakrzewski has more than 25 years of experience in the healthcare industry. His career started with Eli Lilly & Company in the USA: He joined as process engineer with responsibility for biologics development & manufacturing (1988-1991), became Senior Financial Analyst (1991-1993) and Head of Manufacturing and Development (1993-1995), then Manager and Director of Corporate Business Development (1995-2003), before being appointed VP Global Corporate Business Development (2003-2005). He was Chief Operating Officer of Reliant Pharmaceuticals (2005-2007), and then joined the biotechnology company Xcellerex as CEO (2007-2010). From 2010 to 2013, he was Chairman and CEO of Amarin Corporation (Ireland), where he remains a director. He has also been a venture partner at Orbimed Advisors, one of the leading VC funds dedicated to the healthcare industry (2010-2011).
Joseph Zakrzewski is a board member with several biotechnology companies in Europe and in the USA, public and private, including Insulet Corporation, Amarin Corporation, Thrasos Therapeutics, Acceleron Pharma, Gliacure Inc., and SiteOne Therapeutics.
A US citizen, Joseph Zakrzewski received a BS in Chemical Engineering and an MS in Biochemical Engineering from Drexel University. He has an MBA in Finance from the University of Indiana.
About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to "make the difference". The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.
Key orphan oncology products at the advanced development stage are:
Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (clonidine Lauriad®): Phase II in severe oral mucositis: Positive final results
Beleodaq® (belinostat): Registered in the US in 2nd-line treatment of peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com
Help employers find you! Check out all the jobs and post your resume.